Proteases are known to play important roles in cell growth control, although the underlying mechanisms are still poorly understood. Here we show that the protease inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal induced cell cycle arrest in platelet-derived growth factor-stimulated human fibroblasts at the G1/S boundary of the cell cycle by inhibiting the proteasome. Inhibition of the proteasome resulted in accumulation of the tumor suppressor p53, which was followed by an increase in the amount of the cyclindependent kinase-inhibitor p21. As a consequence, both phosphorylation and activity of the cyclin-dependent kinase 2/cyclin E complex were inhibited. We further observed that the retinoblastoma gene product, pRb, remained in the hypophosphorylated state, thus preventing cells from progression into the S-phase. These studies strongly support the hypothesis that the proteasome is a key regulator in the Gl-phase of cell cycle progression.
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There is evidence that intracellular proteases play a dominant role in cell cycle control. Accordingly, antiproliferative effects are shown by some cell-permeable protease inhibitors. For example, the lipid soluble derivative of E-64, E-64d, an inhibitor of cathepsins and calpains, has been shown to arrest squamous cell carcinoma cells in metaphase (1) . Cathepsins are known as acid cysteine proteases in contrast to the neutral, Ca2+-requiring cysteine proteases, calpains (calpain 1 and calpain 2). Mellgren and coworkers (2) also suggested that calpains participate in cell growth regulation since benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone, which is thought to inhibit calpains, reduced proliferation of human TE2 (simian virus 40-transformed human esophageal epithelial cells) and C-33A cells (human cervical carcinoma cells). In vascular smooth muscle cells, N-acetyl-L-leucinyl-L-leucinyl-Lnorleucinal (LLnL) (calpain inhibitor 1) caused a repression of platelet-derived growth factor-(PDGF), as well as seruminduced cell cycle progression before G1/S transition (3) . Unfortunately, these commonly used thiol protease inhibitors are not highly selective, making it difficult to precisely define the intracellular targets. LLnL, for example, is not selective for calpains, but inhibits also cathepsin L (4), as well as the proteasome complex (5) . Consequently, the assumption that calpains function in cell cycle control (2, 3) , remains to be verified. Furthermore, it is not known which distinct step within the cell cycle is affected by calpain inhibitors resulting in G1 arrest. Interestingly, cyclin B degradation, which requires ubiquitin-conjugation (6), can be inhibited by LLnL (7) . In previous studies in which we addressed the question if proteolytic activity is required to allow confluent cultures to mitogenically respond to PDGF, we noticed that LLnL strongly inhibited PDGF-induced proliferation. We therefore studied the effect of LLnL in PDGF-AB-stimulated human fibroblasts to determine (i) the protease(s) that is/are inhibited by LLnL, (ii) the target of the protease(s), and (iii) the cell cycle events that are affected by LLnL. ) were seeded in 6-well plates and cultured as described above. Cells were lysed for 15 min at 4°C (10 mM Tris-HCl, pH 7.4/5 mM KCl/2 mM MgCl/1 mM DTT/1% Triton X-100/10 mM Na2H2P207/2 mM Na3VO4/10 mM NaF/0.3 ,uM aprotinin/ 0.1 ,uM soybean trypsin inhibitor/60 ,uM phenylmethylsulfonyl fluoride/0.4 mM iodoacetamide/5 ,uM pepstatin/4 ,uM leupeptin), and nuclei were pelleted by centrifugation at 400 X g (9) and solubilized in SDS sample buffer (10) . Proteins of the supernatant were precipitated (11) 8 .0/150 mM NaCl/0.05% Tween 20) .
MATERIALS AND METHODS
For immunodetection, membranes were incubated for 1.5-3 h with primary and for 1.5 h with secondary antibodies. Western blotting was performed with anti-pRb antibodies, anti-cdk2 antibodies, anti-cyclin E antibodies, or anti-p53 antibodies (0.1 jig/ml; all from Santa Cruz Biotechnology)
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followed by anti-rabbit alkaline phosphatase-conjugated antibody (1:30,000; Sigma) using 4-nitroblue tetrazolium chloride (Boehringer Mannheim) and 5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim) as a detection system, and with anti-ubiquitin antibodies (1:10; Sigma) and anti-rabbit peroxidase-conjugated antibody (1:1000; Dako), followed by development with 4-chloro-1-naphthol and 3,3'-diaminobenzidine.
Immunoprecipitation. Cells (8 x 105) per well (6-well plate) were lysed for 20 min at 4°C in RIPA buffer for cdk2 and cyclin E immunoprecipitation (50 mM Tris HCl, pH 7.5/1% sodium deoxycholate/1% Triton X-100/0.1% SDS, phosphatase and protease inhibitors as described) or in modified RIPA buffer for p53 immunoprecipitation (1% Nonidet P-40 instead of Triton X-100) and immunoprecipitated for 2-4 h at 4°C with anti-cyclin E, anti-cdk2, or anti-p53 antibodies, respectively (10 ,ug; Santa Cruz Biotechnology), covalently coupled to protein A-Sepharose (12.5 mg; Sigma). After SDS/PAGE (10-20% for cdk2 and cyclin E detection, 7.5% for ubiquitin detection), Western blotting with anti-cdk2, anti-cyclin E, or antiubiquitin antibodies was performed as described above.
Histone Hi Kinase Assay. Kinase (Fig. 1A) .
In contrast, the non cell-permeable thiol protease inhibitor E-64 (25 ,uM), Calpastatin-related peptide (10 ,tM), and leupeptin (2 ,uM) failed to decrease PDGF-induced proliferation (data not shown). Ectoproteolytic activity in the cell culture medium was only slightly increased in response to PDGF (1.5-fold) and not affected by LLnL (data not shown). We therefore conclude that LLnL acts via intracellular mechanisms.
As (13, 14) ], they should be useful probes to distinguish between calpain, cathepsin, and proteasome function in vivo.
For these reasons, we compared the effects of the following thiol protease and proteasome inhibitors and studied their rank order of potencies: E-64d [inhibits calpains and cathepsins (4)], MG-132. LLnL, and LLM. The fact that E-64d (100 ,uM), failed to impair PDGF-induced proliferation in our experiments (Fig. 1A) Flow cytometric analysis demonstrated that, in the presence of PDGF and LLnL, FH109 cells were arrested in the Go/G1-phase of the cell cycle (Fig. 1B) clear shift to lower electrophoretic mobility (Fig. 24) (16) . In accordance with the work of Mittnacht and Weinberg (9), the hyperphosphorylated species were observed only in the cytosolic compartment. However, in the presence of LLnL, we exclusively observed hypophosphorylated pRb in the nucleus and no slower migrating pRb in the cytosol (Fig. 2A) Since pRb phosphorylation is believed to be the final control point for G1/S transition, we next examined the upstream regulators of pRb phosphorylation, namely G1 cyclins and cdks. They are known to regulate cell cycle progression and there is evidence for a significant role of cdk2 and cyclin E in phosphorylating pRb in late G1 (17) (18) (19) . The enzymatic activity of cdk2 is regulated at three different levels: complex formation with cyclin E, activation by phosphorylation of Thr-160 by cdk-activating kinase, and inactivation by phosphorylation of Thr-14 and Tyr-15 (20) and inhibition by a group of small proteins known as p21 and p27 (for review see ref. 21) . Using Western blot analysis (data not shown), we have detected that in FH109 cells, PDGF caused an increase in cyclin E levels, which were highest at the G1/S boundary (18 h after PDGF treatment) and declined in early S-phase (22 h after PDGF treatment), as well as an increase in cdk2 phosphorylation with a maximum in late G1, but persisting in early S-phase. Accordingly, association of cyclin E with cdk2 was highest at the G1/S boundary (data not shown). Fig. 2 B (Left) and C show the results of Western blot analysis of cdk2 content and the histone Hi kinase assay of immunoprecipitates obtained with anti-cyclin E antibodies 18 h after PDGF treatment in the absence or presence of LLnL. In response to PDGF, a faster migrating form of cdk2 was coimmunoprecipitated with cyclin E (Fig. 2B, Left, lane 2) , which represents phosphorylated and hence activated cdk2 (19, 20) . According to a 7-fold increase of cdk2 phosphorylation, an 11-fold increase of kinase activity with histone Hi as a substrate was observed in immunoprecipitates of PDGF-treated cells. In the presence of LLnL, both phosphorylation (Fig. 2B, 70-85%) and histone Hi kinase activity of cdk2 were strongly reduced (Fig. 2C) . The same inhibiting effect on cdk2 phosphorylation could be detected in the presence of MG-132 (400 nM, data not shown). Immunoprecipitation with anti-cdk2 antibodies was performed to investigate if association with cyclin E was altered by LLnL (Fig. 2B, Right) . Because neither the amounts of cyclin E or cdk2 were affected by LLnL nor the interaction between cyclin E and cdk2, the most likely explanation for the inhibition of phosphorylation and kinase activity of the cdk2/cyclin E complex was the presence of cdk inhibitors. As noted above, cdk2 activity is further regulated by the inhibitors p21 and p27, which associate with the cdk2/cyclin E complex. On the one hand, the protein p21 (also known as WAF1 and Cipl) can prevent phosphorylation of the complex (22, 23) and on the other hand inactivate the phosphorylated complex directly (24) . FH109 cells were therefore metabolically labeled with [35S]methionine to detect associated proteins in cyclin E immunoprecipitates. p21 was identified by subsequent Western blotting. In PDGF-treated cells, only a small amount of p21 could be detected in the immunoprecipitates, whereas LLnL led to a 4.5-fold increase of p21 associated with the cyclin E/cdk2 complex (Fig. 2D) . These results strongly support the conclusion that p21 inhibits phosphorylation and activation of the cdk2/cyclin E complex in response to LLnL exposure.
There is strong evidence for an involvement of the tumor suppressor p53 in regulating p21 expression (25) . It is further known that p53 is degraded by the ubiquitin-proteasome system in vitro and possibly in vivo (26, 27) . Because our proliferation studies (Fig. 1A) indicated that LLnL inhibits the proteasome complex, it was intriguing to examine whether LLnL blocks p53 degradation, which would explain the elevated level of cdk2/cyclin E complex-associated p21. Total cell proteins were separated on SDS/PAGE and immunoblotted with anti-p53 antibodies 18 h after PDGF treatment in the absence and presence of LLnL. In the presence of LLnL, a significantly higher level of p53 was observed (Fig. 3, Left, lane  3) . The same results were obtained using the proteasome selective compound MG-132 (400 nM, data not shown). After immunoprecipitation with anti-p53 antibodies and immunodetection with anti-ubiquitin antibodies, we revealed a 3.5-fold accumulation of ubiquitin-conjugated p53 (Fig. 3, Right) . These results support the hypothesis that LLnL increases p21 Ctr associated with cyclin E/cdk2 by inhibiting proteasomemediated p53 degradation.
Ubiquitination of p53 is a multi-step process involving three different enzymes (29) : Ub-activating enzyme (El) catalyzes the initial ATP-dependent step, resulting in the formation of an El-bound ubiquitinyl adenylate. The activated Ub is then transferred to a Ub-conjugating enzyme (E2) and subsequently to the substrate. The last step requires an additional enzyme, Ub-protein ligase (E3). To prove our assumption that LLnL could block degradation of p53 via proteasome inhibition, we studied the effects of the dipeptide Leu-Ala, an inhibitor of the Ub-protein ligase (E3) (30) . If our hypothesis was correct, then Leu-Ala would mimic the effects of LLnL on FH109 proliferation and cell cycle. The experiments revealed a 40% decrease (37 ± 4%, n = 4) of PDGF-induced proliferation in the presence of 100 mM Leu-Ala. Accordingly, phosphorylation and hence activation of cdk2 was suppressed (Fig. 4) . In summary, these results further support our previous conclusion that one major target of LLnL is the proteasome.
LLnL was reported to be toxic in some cell lines (7) at high concentrations and long exposure periods (>24 h). Toxicity may be caused by DNA damage, known to increase p53 levels. The following observations suggest that the p53 increase shown here is the result of the action of LLnL on the proteasome: (i) the effect of LLnL on proliferation was reversible, (ii) the increase of p53 was accompanied by an accumulation of ubiquitin-conjugated p53, (iii) the effects could be mimicked by Leu-Ala, a Ub ligase (E3) inhibitor and by MG-132, a selective compound for the proteasome.
In general, due to its rapid degradation, p53 has a short half-life in nontransformed cells. We propose the model that LLnL increases steady-state levels of p53 via inhibition of the proteasome. p53 induces expression of p21, which in turn inhibits phosphorylation of cdk2 and activation of the cdk2/ cyclin E complex. As a consequence, pRb remains in the hypophosphorylated state resulting in cell cycle arrest at the GI/S boundary (Fig. 5) .
This model fits well with very recent results obtained by Pagano et al. (31) who found that LLnL blocks p27 degradation via the ubiquitin-proteasome system in human osteosarcoma cells. The fact that, in their studies, p21 levels remained unaffected is in agreement with our results, because the osteosarcoma cells used by Pagano et al. (31) lack the gene for p53 and therefore cannot regulate the expression of p21 via this pathway. Together these two investigations strongly support the conclusion that the proteasome is a key regulator of G1 events.
As mentioned, DNA damage also induces expression of p53 and hence p21 (32) , but the mechanisms leading to the p53 increase are still unknown. Here, we have shown for the first time, to our knowledge, that in intact cells the inhibition of the proteasome complex results in an increase of intracellular p53 leading to cell cycle arrest at the G1/S boundary. It is therefore tempting to speculate that DNA damage causes induction of a system-blocking proteasome function, which results in accumulation of cdk inhibitors.
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